Discriminative stimulus properties of idazoxan: Mediation by both α2 adrenoceptor antagonism and 5-HT1A receptor agonism

Drug Development Research

Volumn 71, Issue 4, 2010, Pages 261-267

  Prus, Adam J ^a   Zornio, Patricia A ^a   Schuck, Candice J ^a   Heerts, Tanya ^a   Jacobson, Sarah M ^a   Winiarski, Dominika A ^a  

^a NORTHERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; GUANFACINE; HALOPERIDOL; IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A AGONIST; YOHIMBINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NONHUMAN; RAT; TASK PERFORMANCE;

EID: 77953908991     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20370     Document Type: Article

References (30)

1. Dekeyne A, Millan MJ. 2006. Discriminative stimulus properties of the selective and highly potent [alpha]2-adrenoceptor agonist, S18616, in rats: mediation by the [alpha]2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin. Neuropharmacology 51:718-726.
2. Doxey JC, Lane AC, Roach AG, Virdee NK. 1984. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn-Schmiedebergs Arch Pharmacol 325:136-144.
3. Goudie AJ, Smith JA, Taylor A, Taylor MA, Tricklebank MD. 1998. Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699-710.
4. Hertel P, Fagerquist MV, Svensson TH. 1999. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105-107.
5. Ichikawa J, Meltzer HY. 1999. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232.
6. Invernizzi RW, Garavaglia C, Samanin R. 2003. The [alpha]2- adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28: 872-879.
7. 1A receptor activation. Psychopharmacology (Berl) 177:373-380.
8. Kuroki T, Meltzer HY, Ichikawa J. 1999. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781. (Pubitemid 29119694)
9. Kwong LL, Smith ER, Davidson JM, Peroutka SJ. 1986. Differential interactions of "prosexual"drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors. Behav Neurosci 100:664-668.
10. Li Z, Ichikawa J, Meltzer HY. 2003. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology 167:315-323. (Pubitemid 36712979)
11. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157-165.
12. Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D. 1993. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 13:264-267.
13. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. 1996. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579. (Pubitemid 126425218)
14. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH. 2005. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327.
15. 3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79-95.
16. Moghaddam B, Bunney BS. 1990. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760. (Pubitemid 20136740)
17. National Research Council. 1996. Guide for laboratory animal facilities and care. Washington, DC: National Research Council.
18. Prus AJ, Jacobson SM. 2009. [alpha]2 adrenoceptor blockade mediates the ability of idazoxan to potentiate raclopride-induced inhibition of conditioned avoidance responding. Chicago, IL: Society for Neuroscience.
19. Prus AJ, Baker LE, Meltzer HY. 2004. Discriminative stimulus properties of 12.5 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199-208.
20. Prus AJ, Philibin SD, Pehrson AL, Porter JH. 2006. Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 125 mg/kg clozapine vs. 50 mg/kg clozapine vs. vehicle. Behav Pharmacol 17:185-194.
21. 2A receptors in the effect of idazoxan with and without dopamine (DA) D2 receptor blockade to enhance cortical DA efflux. San Diego, CA: Society for Neuroscience.
22. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237.
23. 1A receptor activation. European Journal of Pharmacology 338:R3-R5.
24. Sanger DJ. 1989. Discriminative stimulus effects of the alpha 2-adrenoceptor antagonist idazoxan. Psychopharmacology (Berl) 99:117-121.
25. Sanger DJ, Schoemaker H. 1992. Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors. Psychopharmacology (Berl) 108:85-92.
26. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
27. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, et al. 1998. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466.
28. Wadenberg ML, Wiker C, Svensson TH. 2007. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191-202.
29. 1A receptor ligands by drug discrimination. Eur J Pharmacol 333: 113-122.
30. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472.